Clinical Trial

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I study evaluating the safety and pharmacokinetics of MBS301 after intravenous administration in patients with HER-2 positive recurrent or metastatic malignant solid tumors
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-02-12; most recent amendment 2024-11-19.
Status change: Not Yet Recruiting → Recruiting 2019-06-26
Trial Details
NCT Number NCT03842085
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions HER2-positive Recurrent or Metastatic Malignant Solid Tumor
Enrollment 34 participants
Start Date 2019-04-11
Primary Completion 2024-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-20